Calcium antagonists for secondary prevention of myocardial infarction: Is there a need to shift from short-acting to long-acting types?

Circulation Journal

Volumn 69, Issue 11, 2005, Pages 1308-1314

  Taniwa, Takaaki ^a   Miyataka, Masaru ^b   Kimura, Akio ^b   Taniguchi, Mitsugu ^b   Hirano, Yutaka ^b   Hayashi, Takahiro ^b   Ishikawa, Kinji ^b  

^a SAKAI MUNICIPAL HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amlodipine; Calcium antagonists; Myocardial infarction; Nifedipine; Secondary prevention

Indexed keywords

AMLODIPINE; BENIDIPINE; CALCIUM ANTAGONIST; EFONIDIPINE; FELODIPINE; MANIDIPINE; MEPIRODIPINE; NIFEDIPINE; NILVADIPINE; NISOLDIPINE; NITRENDIPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HALF LIFE; FEMALE; HAZARD ASSESSMENT; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS;

AMLODIPINE; CALCIUM; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NIFEDIPINE; RETROSPECTIVE STUDIES;

EID: 27644479486     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1308     Document Type: Article

References (24)

1. The Danish Study Group on verapamil in myocardial infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516-528.
2. Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind, placebo-controlled comparison. Circulation 1984; 69: 740-747.
3. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
4. Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997; 95: 2368-2373.
5. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: FACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on management of acute myocardial infarction). Circulation 1999; 100: 1016-1030.
6. Kinoshita M, Ishikawa K, Inoue H, Kanbara Y, Kanmatsuse K, Saitou Y, et al. Guidelines for the secondary prevention of myocardial infarction. Jpn Circ J 2000; 64(Suppl IV): 1081-1127 (in Japanese).
7. Opie LH, Messerli FH. Nifedipine and mortality: Grave defects in the dossier. Circulation 1995; 92: 1068-1073.
8. Selwyn AP, Welman E, Fox K, Horlock P, Pratt T, Klein M. The effects of nifedipine on acute experimental myocardial ischemia and infarction in dogs. Circ Res 1979; 44: 16-23.
9. Ishikawa K, Kimura A, Taniwa T, Takenaka T, Hayashi T, Kanamasa K on behalf of the Secondary Prevention Group. Modification of treatment strategies over a period of 14 years has markedly reduced cardiac events among post-myocardial infarction patients. Circ J 2002; 66: 881-885.
10. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
11. Forrester JS, Diamond GA, Swan HJC. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol 1977; 39: 137-145.
12. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, editor. Heart disease, 5th edn. Philadelphia: Saunders; 1997; 742-779.
13. Borzak S, Fenton T, Glasser SP, Shook TL, MacCallum G, Young PM, et al. Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance and anginal symptoms in patients with stable angina pectoris. J Am Coll Cardiol 1993; 21: 1605-1611.
14. von Arnim T for the TIBBS investigators. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995; 25: 231-238.
15. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ on behalf of the TIBET study group. The Total Ischaemic Burden European Trial (TIBET): Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96-103.
16. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004; 292: 2217-2226.
17. Alderman MH, Cohen H, Roqué R, Madhavan S. Effect of longacting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-598.
18. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
20. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
21. Tani S, Watanabe I, Nagao K, Kikushima K, Watanabe K, Anazawa T, et al. Efficacy of calcium channel blocker in the secondary prevention of myocardial infarction: Retrospective analysis of the 10-year prognosis of coronary thrombolysis-treated patients. Circ J 2004; 68: 853-859.
22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
23. The Japanese -blockers and Calcium antagonists Myocardial Infarction (JBCMI) investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969-973.
24. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on management of patients with chronic stable angina). Circulation 1999; 99: 2829-2848.